Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

EAY191 Molecular Analysis for Combination Therapy Choice (ComboMATCH)

99 years and younger
All genders
The ComboMATCH precision medicine trial will include multiple components: this non-treatment ComboMATCH Registration Trial, an informatics component for specimen and genomic data management, and multiple ComboMATCH Treatment Trials.
Learn More

UPCC 23922 A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of H

99 years and younger
All genders
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Learn More

UPCC 23423: Full Protocol Title A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT

99 years and younger
All genders
This study tests an investigational drug called LANRA as a possible treatment for people with relapsed or refractory FLT3-mutated AML. This study will take place in 2 parts. In Part 1 (dose escalation), the main purpose is to determine the maximal dose of LANRA that can be safely administered and …
Learn More

UPCC 19123 ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer

99 years and younger
All genders
Please refer to Protocol Section 1 (Objectives). Please refer to Protocol Section 14.3 (Analysis of Secondary Endpoints). Please refer to Protocol Section 14.1. (Study Design/Endpoints)
Learn More

UPCC 33923: Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 26423 Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCR and 4-1BB Signaling Domains in Combination with CD33KO-HSPC in Subjects with Refractory or Relapsed Acute Myeloid Leukemia

99 years and younger
All genders
Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints).
Learn More

UPCC 09422: Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia

99 years and younger
All genders
This study will randomly assign hospitals to deliver either specialty palliative care or primary palliative care for patients with AML. Our site will provide participants with specialty palliative care. This study will enroll patients, their caregivers, and key informants (health care clinician or leader) to provide perspectives on palliative care.
Learn More

UPCC 20222 Protocol to permit collection of circulating biomarkers in pancreatic cancer

99 years and younger
All genders
Please refer to Protocol
Learn More

UPCC 12223: A Phase 2, Open-label, Multicenter Study Investigating RP3 Oncolytic Immunotherapy in Combination with First- or Second-line Therapy in Patients with Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma

99 years and younger
All genders
Please refer to Protocol section 3 (Objectives and Endpoints). Please refer to Protocol section 3 (Objectives and Endpoints). Please refer to Protocol section 3 (Objectives and Endpoints).
Learn More

UPCC 09223: A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination with Atezolizumab and bevacizumab for the Treatment of Patients with Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma

99 years and younger
All genders
Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints) Please refer to Section 3.1 of the full protocol (Objectives and Endpoints)
Learn More
71 - 80 of 206